Dr. Edwin A. Gomez, M.D.
Psychiatry (Psychiatry Physician)
At a glance
- Years since graduation
- 29
- In the NPI registry since
- 2006
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Psychiatry Physician primary
FL license ME97741 -
Child & Adolescent Psychiatry Physician
FL license ME97741
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Medical groups
- David Lawrence Mental Health Center, Inc (32 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 21 | 17 |
| Psychiatric diagnostic evaluation with medical services | 12 | 12 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Payments from drug and device companies
In 2025, 4 companies reported 12 payments worth $1,639 in total to this clinician.
| Neurocrine Biosciences, Inc. | $1,477 |
|---|---|
| Abbott Laboratories | $98.68 |
| E.r. Squibb & Sons, L.l.c. | $34.42 |
| Vanda Pharmaceuticals Inc. | $28.92 |
| Travel and Lodging | $1,146 |
|---|---|
| Food and Beverage | $493 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Neurocrine Biosciences, Inc. Oct 3, 2025 | Travel and Lodging travel to New Orleans, LA · in-kind | $586 |
| Neurocrine Biosciences, Inc. Oct 3, 2025 | Travel and Lodging travel to New Orleans, LA · in-kind | $223 |
| Neurocrine Biosciences, Inc. Oct 4, 2025 | Travel and Lodging travel to New Orleans, LA · in-kind | $223 |
| Neurocrine Biosciences, Inc. Oct 3, 2025 | Travel and Lodging travel to New Orleans, LA · in-kind | $115 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 21 industry-funded studies in 2025, from 7 companies. The companies reported $11,049,894 in research payments for these studies, mostly to the institutions running them.
- Study to Assess Safety and Effectiveness of Slowly Increasing Dose and Food Effect of KarXT in Participants With Schizophrenia
E.r. Squibb & Sons, L.l.c. · Completed · NCT06572449 - A 21-Week, Multicenter, Open-Label, Multiple-Dose Trial to Assess the Comparative Bioavailability of Olanzapine Prolonged-Release Suspension for Subcutaneous Administration (TV-44749) to Oral Olanzapine (European Refe…
Teva Pharmaceuticals USA, Inc. - A Multi-center, Open-label, Randomized, Parallel-group Trial to Characterize the Pharmacokinetics of Three SC Olanzapine Extended-release Formulations with Different Release Rates Following Single Administration in Pa…
Teva Pharmaceuticals USA, Inc. - A Phase 3, Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder
E.r. Squibb & Sons, L.l.c. - An 8-week Open-label, Multicenter Randomized Study of Accelerated and Slower Switching to Xanomeline/Trospium Following Atypical Antipsychotic Treatment to Assess the Safety, Tolerability, and Efficacy in Participants…
E.r. Squibb & Sons, L.l.c. - A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended…
Teva Pharmaceuticals USA, Inc. - A 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 in patie…
Boehringer Ingelheim Pharmaceuticals, Inc. - An Open-label Study to Assess the Long-term Safety, Tolerability, and Efficacy of KarXT in Adult Patients With Schizophrenia (EMERGENT-5)
E.r. Squibb & Sons, L.l.c. · Completed · NCT04820309 - A Study to Evaluate the Safety, Tolerability, and PK of an Injectable Form of KarXT
E.r. Squibb & Sons, L.l.c. · Recruiting · NCT07061288 - A Randomized, Double-blind, Placebo-controlled, Parallel-group Study of Lumateperone for the Prevention of Relapse in Patients With Schizophrenia
Iti, Inc. (d/b/a Intra-cellular Therapies, Inc.)
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.